Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Jun 16, 2023; 12(3): 18-24
Published online Jun 16, 2023. doi: 10.5497/wjp.v12.i3.18
Commentary: Discussing the antidepressant potential of silymarin
Claire E Manhard, Brandon Lucke-Wold
Claire E Manhard, Brandon Lucke-Wold, Department of Neurosurgery, University of Florida, Gainesville, FL 32608, United States
Author contributions: Manhard CE and Lucke-Wold B both designed and wrote this minireview (commentary).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Brandon Lucke-Wold, MD, PhD, Neurosurgeon, Department of Neurosurgery, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, United States.
Received: January 20, 2023
Peer-review started: January 20, 2023
First decision: April 28, 2023
Revised: May 10, 2023
Accepted: May 31, 2023
Article in press: May 31, 2023
Published online: June 16, 2023
Core Tip

Core Tip: There are several reviews focused on the role of silymarin (SILY) in chronic diseases, however, there is a paucity of literature reviewing the potential antidepressant effects of SILY. This commentary serves as a discussion of the recent findings regarding the antioxidant, anti-inflammatory, and antidepressant-like potential of SILY in mice and as a catalyst for future discovery in phytochemistry.